Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Amyotrophic Lateral Sclerosis (ALS): early-phase trial registry
10 of 19 indexed Amyotrophic Lateral Sclerosis (ALS) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 10 currently recruiting · #902 of 28,707 conditions by registered trial count
Amyotrophic Lateral Sclerosis (ALS): 19 US clinical trials tracked, 10 recruiting.
Amyotrophic Lateral Sclerosis (ALS) is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Duke University, running 2 of these trials.
Enrollment posture brief
Registry condition amyotrophic-lateral-sclerosis-als
OPEN 10 | RECR 53% | LATE 0 | EARLY 9 | RANK #902 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Colorectal Cancer Metastatic (53% recruiting · 19 trials)
Amyotrophic Lateral Sclerosis (ALS) lists 10 open slots (53% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Amyotrophic Lateral Sclerosis (ALS) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Amyotrophic Lateral Sclerosis (ALS) is recruiting above its size-band peers.
10 of 19 indexed trials (52.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Amyotrophic Lateral Sclerosis (ALS) trials is spread across many organizations.
Duke University accounts for 2 of 19 trials (10.5%). 18 distinct sponsors appear on at least one study for this condition label.
-
Typical Amyotrophic Lateral Sclerosis (ALS) enrolment sits around 97 participants.
Median target enrolment is 97 among the 19 trials that report a genuine target (sentinel values excluded). 10 of those (52.6%) plan for fewer than 100 participants.
-
Amyotrophic Lateral Sclerosis (ALS) research is mostly interventional.
14 interventional and 5 observational studies make up this index (73.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
Retinal Imaging in Neurodegenerative Disease
Duke University
NCT03233646
Healing ALS Registry Observational Study (HAROS)
Healing Advocates Registry and Ministry
NCT07233148
UPenn Observational Research Repository on Neurodegenerative Disease
University of Pennsylvania
NCT04715399
Examining Interactions Between PALS and Caregivers
Penn State University
NCT06819124
Study of COYA 302 for the Treatment of ALS
Coya Therapeutics
NCT07161999
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
PhenoNet
NCT07142291
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Ashvattha Therapeutics
NCT05395624
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
Dallas VA Medical Center
NCT04244630
Intestinal Microbiome Transplant in ALS
Duke University
NCT07017946
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
Nova Southeastern University
NCT07187388
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
Novartis Pharmaceuticals
NCT06643481
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Zydus Therapeutics
NCT07023835
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Beth Israel Deaconess Medical Center
NCT02118805
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
Synapse Biomedical
NCT01605006
Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
Massachusetts General Hospital
NCT02559869
A First in Human Study of ORT247 in Healthy Volunteers
Orthogonal Neuroscience
NCT06769620
Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS
Bronx VA Medical Center
NCT02469675
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
Yunxia Wang, MD
NCT01232738
Remotely Supervised tDCS for Slowing ALS Disease Progression
University of Illinois at Chicago
NCT04866771
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Amyotrophic Lateral Sclerosis (ALS) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Amyotrophic Lateral Sclerosis (ALS) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Amyotrophic Lateral Sclerosis (ALS) page
19 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Amyotrophic Lateral Sclerosis (ALS) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Duke University sponsors the most Amyotrophic Lateral Sclerosis (ALS) trials on record, review their full trial history before evaluating a specific study. See Duke University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Amyotrophic Lateral Sclerosis (ALS) condition card totals 19 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.